Logo image of CMMB

CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Fundamental Analysis

NASDAQ:CMMB - Nasdaq - US16385C1045 - ADR - Currency: USD

1.25  -0.23 (-15.54%)

After market: 1.26 +0.01 (+0.8%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CMMB. CMMB was compared to 572 industry peers in the Biotechnology industry. The financial health of CMMB is average, but there are quite some concerns on its profitability. CMMB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CMMB has reported negative net income.
In the past 5 years CMMB always reported negative net income.
CMMB had a negative operating cash flow in each of the past 5 years.
CMMB Yearly Net Income VS EBIT VS OCF VS FCFCMMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -68.90%, CMMB is not doing good in the industry: 64.57% of the companies in the same industry are doing better.
CMMB has a Return On Equity of -88.24%. This is comparable to the rest of the industry: CMMB outperforms 49.91% of its industry peers.
Industry RankSector Rank
ROA -68.9%
ROE -88.24%
ROIC N/A
ROA(3y)-64.32%
ROA(5y)N/A
ROE(3y)-79.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMMB Yearly ROA, ROE, ROICCMMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

CMMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMMB Yearly Profit, Operating, Gross MarginsCMMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, CMMB has more shares outstanding
CMMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMMB Yearly Shares OutstandingCMMB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M
CMMB Yearly Total Debt VS Total AssetsCMMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

There is no outstanding debt for CMMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
CMMB Yearly LT Debt VS Equity VS FCFCMMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 4.57 indicates that CMMB has no problem at all paying its short term obligations.
With a Current ratio value of 4.57, CMMB perfoms like the industry average, outperforming 50.79% of the companies in the same industry.
CMMB has a Quick Ratio of 4.57. This indicates that CMMB is financially healthy and has no problem in meeting its short term obligations.
CMMB's Quick ratio of 4.57 is in line compared to the rest of the industry. CMMB outperforms 52.36% of its industry peers.
Industry RankSector Rank
Current Ratio 4.57
Quick Ratio 4.57
CMMB Yearly Current Assets VS Current LiabilitesCMMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 97.84% over the past year.
EPS 1Y (TTM)97.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CMMB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.04% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-237.5%
EPS Next 2Y-80.28%
EPS Next 3Y-80.87%
EPS Next 5Y9.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMMB Yearly Revenue VS EstimatesCMMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
CMMB Yearly EPS VS EstimatesCMMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMMB. In the last year negative earnings were reported.
Also next year CMMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMMB Price Earnings VS Forward Price EarningsCMMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMMB Per share dataCMMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as CMMB's earnings are expected to decrease with -80.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-80.28%
EPS Next 3Y-80.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CMMB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHEMOMAB THERAPEUTICS LTD

NASDAQ:CMMB (3/7/2025, 8:15:23 PM)

After market: 1.26 +0.01 (+0.8%)

1.25

-0.23 (-15.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05 2025-03-05/amc
Earnings (Next)05-07 2025-05-07
Inst Owners16.69%
Inst Owner Change-8.28%
Ins Owners10.03%
Ins Owner Change0%
Market Cap23.57M
Analysts84.44
Price Target9.18 (634.4%)
Short Float %4.14%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-892.06%
Min EPS beat(2)-1720.73%
Max EPS beat(2)-63.4%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.5%
PT rev (3m)12.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-710%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpSN/A
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.9%
ROE -88.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.32%
ROA(5y)N/A
ROE(3y)-79.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset TurnoverN/A
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.57
Quick Ratio 4.57
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)307.05%
Cap/Depr(5y)231.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.18%
EPS Next Y-237.5%
EPS Next 2Y-80.28%
EPS Next 3Y-80.87%
EPS Next 5Y9.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y49.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.91%
OCF growth 3YN/A
OCF growth 5YN/A